Nexalin Technology Announces New Secondary Analysis of Previously Published Clinical Trial Data Reveals Previously Unreported Improvements in Memory, Comprehension and Language Function in Alzheimer's Patients; ADAS-Cog Subscale Analysis to Guide Design of Planned U.S. Alzheimer's Pilot Study

New analysis of ADAS-Cog data from the company’s randomized, sham-controlled trial reports specific cognitive-domain improvements tied to memory in Alzheimer’s patients, building on earlier publications in the Journal of Alzheimer’s Disease and Radiology. The update is supportive of clinical signals but provides no quantified effect sizes in the excerpt.